NASDAQ$CBUS

Cibus Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Cibus reported its Q4 2024 financial results and provided a business update.

Cibus reported a net loss in Q4 2024 while continuing to progress on commercialization and development of key agricultural traits. Revenue remained modest, and the company implemented cost-saving measures and pursued strategic partnerships to strengthen its pipeline.

  • Q4 2024 revenue was $1,212,000.
  • Net loss for the quarter was $25,804,000, improving from a much larger loss in Q4 2023.
  • R&D expenses were reduced to $12,433,000 for the quarter.
  • Cash and cash equivalents stood at $14,433,000 at the end of Q4 2024.

Headline financials

Total Revenue

$1.21M

Previous: $1.1M+9.9%
EPS (adj)

-$0.87

Previous: -$1.27+31.5%
Net Income

-$25.8M

Previous: -$277M+90.7%
Operating Income

-$18M

Previous: -$269M+93.3%

Revenue & EPS history

Cibus · Revenue · Quarterly

$1.21M

Q4 2024+9.9%vs Q4 2023
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Forward guidance

Cibus plans to continue advancing its commercialization efforts across rice, canola, and soybean traits, and to expand its partnerships and revenue streams in 2025.

Tailwinds

  • Expansion of commercial relationships with rice seed companies across North and South America.
  • First trait validation trials in Latin America expected in 2025.
  • Successful HT2 trait edits in soybean plants positioning for expanded development.
  • Continued progress on partner-funded sustainable ingredient projects.
  • Field trials for multiple disease resistance modes of action in canola planned for 2025.

Headwinds

  • Low quarterly revenue despite active development pipeline.
  • Significant quarterly net loss and ongoing operating expenses.
  • High royalty liability interest expenses impacting financials.
  • Dependence on future regulatory approvals for commercialization.
  • Reliance on additional financing and strategic alternatives under evaluation.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.1%

Avg return

Earnings day

-2.2%

Avg return

5 days after

-12.4%

Avg return

30 days after

37%

13 / 35 earnings

Positive

+23.6%

Q4 2019

Best reaction

-25.1%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.8%-10.3%
Q4 2025-16.7%-24.7%-56.8%
Q3 2025-0.8%+1.6%+28.8%
Q2 2025-3.5%-11.6%-7.5%
Q1 2025-7.8%-8.1%-29.4%
Q4 2024-6.4%-9.6%-23.7%
Q3 2024+14.5%+15.2%-8.9%
Q2 2024-9.2%+2.7%-42.4%
Q1 2024+2.2%+9.5%-37.5%
Q4 2023-0.7%+2.2%+7.4%
Q3 2023+17.0%+5.0%-8.8%
Q2 2023-9.7%-13.8%-19.8%
Q1 2023-3.6%-8.3%-15.8%
Q4 2022+1.6%-0.7%-21.5%
Q3 2022-1.4%-7.7%+22.5%
Q2 2022+12.4%+4.3%-11.6%
Q1 2022-17.3%-27.4%-60.0%
Q4 2021-2.8%-21.3%-20.6%
Q3 2021-7.4%-9.0%-41.9%
Q2 2021+12.0%+15.1%+19.9%
Q1 2021+4.6%+3.3%-17.4%
Q4 2020-25.1%-24.7%-35.6%
Q3 2020-1.4%-4.0%-44.3%
Q2 2020-6.6%+0.2%-8.3%
Q1 2020-15.0%-9.4%+27.9%
Q4 2019+23.6%+22.7%-10.1%
Q3 2019-9.7%-10.2%-16.3%
Q2 2019+2.7%-13.1%-23.9%
Q1 2019-3.5%-6.7%-9.3%
Q4 2018+8.3%+20.0%+34.0%
Q3 2018-2.9%-4.9%-22.1%
Q2 2018-0.7%-3.1%-10.8%
Q1 2018+1.9%+22.1%+28.1%
Q4 2017+6.4%+18.8%+16.9%
Q3 2017+7.8%+8.2%-2.2%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro